Silver Book Fact

In individuals with persistent low back pain, tanezumab, a humanized anti-nerve growth factor antibody, showed clinical and statistical analgesic efficacy that was superior to placebo and naproxen.

Katz, Nathaniel, David G Borenstein, Charles Birbara, Candace Bramson, Mary Anne Nemeth, Mike D Smith, and Mark T Brown. Efficacy and Safety of Tanezumab in the Treatment of Chronic Low Back Pain. Pain. 2011; 152(10): 2248-58. http://www.painjournalonline.com/article/S0304-3959%2811%2900316-2/abstract

Reference

Title
Efficacy and Safety of Tanezumab in the Treatment of Chronic Low Back Pain
Publication
Pain
Publication Date
2011
Authors
Katz, Nathaniel, David G Borenstein, Charles Birbara, Candace Bramson, Mary Anne Nemeth, Mike D Smith, and Mark T Brown
Volume & Issue
Volume 152, Issue 10
Pages
2248-58
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • An opiate agonist often used for persistent pain, tramadol was found in one meta-analysis to significantly reduce neuropathic pain when compared to placebo.  
  • Antiepileptic drugs relieve persistent neuropathic pain. One meta-analysis found gabapentin to be associated with moderate benefit (equivalent to 30% pain relief) in close to 1 in 2 patients, and…  
  • Advances in neuroimaging will continue to offer information on the brain’s functioning and how it correlates to the pain experience.  
  • Resolvins, a family of lipid mediators, have shown potential in resolving persistent inflammatory pain.  
  • In individuals with persistent low back pain, tanezumab, a humanized anti-nerve growth factor antibody, showed clinical and statistical analgesic efficacy that was superior to placebo and naproxen.